metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Ductopenia asociada a hepatitis por citomegalovirus en un paciente portador de t...
Journal Information
Vol. 26. Issue 1.
Pages 26-28 (January 2003)
Share
Share
Download PDF
More article options
Vol. 26. Issue 1.
Pages 26-28 (January 2003)
Full text access
Ductopenia asociada a hepatitis por citomegalovirus en un paciente portador de trasplante cardíaco
Cytomegalovirus Hepatitis And Ductopenia In A Heart Transplant Recipient
Visits
4377
G. Clementec, M. Salcedoc, O. Núñezc, J. Barrioc, R. Bañaresc, A. de Diegoc, J.L. Pérez Callec,
Corresponding author
jlperezc@medynet.com

Correspondencia: Dr. J.L. Pérez Calle. Tucán, 7, esc. B, 1.o dcha. 28025 Madrid. España.
, E. Álvareza, J. Palomob
a Departamento de Anatomía Patológica Hospital General Universitario Gregorio Marañón. Madrid. España
b Servicio de Cardiología. Hospital General Universitario Gregorio Marañón. Madrid. España
c Servicio de Aparato Digestivo. Unidad de Trasplante Hepático Hospital General Universitario Gregorio Marañón. Madrid. España
This item has received
Article information
Resumen

El citomegalovirus (CMV) es un patógeno importante en los pacientes trasplantados, tanto por sus mecanismos de lesión directa como por sus efectos indirectos. La relación entre el mismo y el rechazo es conocida desde hace años. Se presenta el caso de un receptor de trasplante cardíaco con un cuadro de hepatitis por CMV asociado a lesiones histológicas de ductopenia, típicas de los fenómenos de rechazo crónico del trasplante hepático. Se analizan los mecanismos que, en el contexto de inmunodepresión e infección por CMV, pueden ocasionar ductopenia.

Cytomegalovirus (CMV) is an important pathogen in transplant recipients due to direct and indirect injury. The relationship between CMV and rejection has been well known for many years. We report a heart transplant recipient with CMV hepatitis and ductopenia, which are characteristic of chronic rejection in liver transplantation. The mechanisms involving CMV and ductopenia in the context of immunosuppression are discussed.

Full text is only aviable in PDF
Biblografía
[1.]
V. Schiffer, G. Mentha, E. Giostra, D. Belli, C. Le Coultre, A. Rohner.
Cytomegalovirus in liver transplantation: incidence and groups at risk.
Schweiz Med Wochenschr, 124 (1994), pp. 631-636
[2.]
J.G. O'Grady, S. Sutherland, F. Harvey, R.Y. Calney, G.J.M. Alexander, P.T. Donaldson, et al.
Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation.
Lancet, 2 (1988), pp. 302-305
[3.]
J.C. Arnold, J.G. O'Grady, G. Otto, B. Kommerell, G.J.M. Alexander, R. Willians.
CMV reinfection/reactivacion after liver transplantation.
Transplant Proc, 23 (1991), pp. 2632-2633
[4.]
M.E. Falagas, D.R. Snydman, R. Ruthazer, J. Griffith, B.G. Werner.
Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group.
Clin Infec Dis, 23 (1996), pp. 292-297
[5.]
R.H. Rubin.
Editorial response: cytomegalovirus disease and allograft loss after organ transplantation.
Clin Infect Dis, 26 (1998), pp. 871-873
[6.]
H.M. Steel, A.J. Murday.
Cytomegalovirus as a cause of morbidity in heart transplantation. The experience of one center.
Transplantation, 62 (1996), pp. 492-496
[7.]
P. Häyry, K. Lemström, E. Von Willebrand, J. Tikkanen, P. Koskinen.
CMV infection and allograft rejection.
Transplant Proc, 30 (1996), pp. 916-917
[8.]
A.H. Orbaek.
Heart allograft vascular disease: an obliterative vascular disease in transplanted hearts.
Atherosclerosis, 142 (1999), pp. 243-263
[9.]
H.R. Rosen, C.L. Corless, J. Rabkin, S. Chou.
Association of cytomegalovirus genotype with graft rejection after liver transplantation.
Transplantation, 66 (1998), pp. 1627-1631
[10.]
A.P. Van der Berg, I.J. Klompmaker, B.G. Hepkema.
Cytomegalovirus infection does not increase the risk of vanishing bile duct syndrome after liver transplantation.
Transpl Int, 9 (1996), pp. S171-S173
[11.]
R.H. Wiesner, J. Ludwig, B. Van Hoek, R.A.F. Krom.
Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure.
Hepatology, 14 (1991), pp. 721-729
[12.]
D. Cosman, N. Fanger, L. Borges.
Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers.
Immunol Rev, 168 (1999), pp. 177-185
[13.]
I. Lautenschlager, K. Hockerstedt, E. Taskinen, E. Von Willebrand.
Expression of adhesion molecules and their ligands in liver allografts during cytomeglovirus and acute rejection.
Transplant Int, 9 (1996), pp. 213-215
[14.]
L.J. Burns, J.C. Pooley, D.J. Walsh, G.M. Vercellotti, M.L. Weber, A. Kovacs.
Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomeglovirus immediate early proteins.
Transplantation, 67 (1999), pp. 137-144
[15.]
I. Lautenschlager, K. Hockerstedt, H. Jalanko, R. Loginov, K. Salmela, E. Taskinen, et al.
Persistent cytomegalovirus in liver allografts with chronic rejection.
[16.]
H.P. Dienes, A.W. Lohse, G. Gerken, P. Schirmacher, H. Gallati, H.F. Lohr, et al.
Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis.
Virchows Arch, 431 (1997), pp. 119-124
[17.]
P.T. Donaldson.
Immunogenetics in liver disease.
Baillieres Clin Gastroenterol, 10 (1996), pp. 533-549
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos